Laboratorios Farmaceuticos Rovi, S.a. · BME:ROVI
Laboratorios Farmaceuticos Rovi — Q1 2026 Earnings Presentation
20 slides from Laboratorios Farmaceuticos Rovi's earnings presentation, May 6, 2026
Slide 1: First quarter of 2026 Financial Results
First quarter of 2026 FINANCIAL RESULTS 6 MAY 2026
Slide 2: Disclaimer
DISCLAIMER This Presentation has been prepared by Laboratorios Farmacéuticos ROVI, S.A. (the “Company”) and comprises the slides for a presentation concerning the Company and its subsidiaries (the “Group”). For the purposes of this disclaimer, “Presentation” means this document, its contents or any
Slide 3: Q1 2026 financial results - highlights
Q1 2026 financial results - highlights • Total revenue stable at €154.7 Mn vs Q1 2025 €152.5 Mn • CDMO performed strongly: +5% YoY to €37.4 Mn in Q1 2026 • Specialty pharmaceutical business: Operating revenue – Okedi® continued its strong momentum: +37% YoY -1.5% vs Q1 2025 – Heparin franchise: -12%
Slide 4: First quarter of 2026 Business Performance
First quarter of 2026 Business Performance Juan López-Belmonte Chairman and Chief Executive Officer
Slide 5: Performance of the specialty pharmaceutical business
Performance of the specialty pharmaceutical business Q1 2026 Specialty pharmaceutical business: -3% YoY Prescription-based pharmaceutical products: -6% YoY 0.6 4.7 0.6 2.1 (9.4) (0.1) (1.1) (1.2) (0.2) €Mn 119.1 115.0 Q1 2025 Enoxaparin Bemiparin Okedi® Neparvis® Volutsa® Orvatez® Other Discounts to
Slide 6: ROVI aspires to become a benchmark player in the LMWH field worldwide
ROVI aspires to become a benchmark player in the LMWH field worldwide -6% 105.5 €Mn Prescription-based 99.3 Heparin sales represented 40% of operating sales revenue in Q1 2026 -6% vs Q1 2025 Q1 2025 Q1 2026 -12% Bemiparin Enoxaparin biosimilar 69.6 61.4 €Mn Heparine franchise(1) • Over 70 years of •
Slide 7: Okedi®: Key growth driver in Q1 2026
Okedi®: Key growth driver in Q1 2026 Okedi® sales ramp-up +37% +10% 17.2 15.7 14.3 14.1 12.6 7.8 8.5 7.1 5.4 5.4 3.8 2.2 3.0 0.6 1.1 0.2 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Strong commercial • Continued growt
Slide 8: Value added CDMO services
Value added CDMO services Our global manufacturing network ROIS Julián ROIS San ROIS Alcalá de Henares ROIS Granada ROIS Phoenix Camarillo Sebastián de los Center of excellent (Madrid) Reyes for injectable API Biologics High-potent vial Fill & finish of PFS(1) Fill & finish of PFS, packaging and man
Slide 9: ISM® Platform opens up new avenues of growth for ROVI
ISM® Platform opens up new avenues of growth for ROVI Overview Key Company Highlights of ISM® Platform • Internally-developed and patented innovative drug-release technology, ISM®(1), which allows for the sustained release of compounds administered by 1 Expected high injection Pop PK(3) model & succ
Slide 10: First quarter of 2026 Financial Performance
First quarter of 2026 Financial Performance Javier López-Belmonte Deputy Chairman and Chief Financial Officer
Slide 11: Revenue level affected by the performance of the prescription-based pharmaceutical products
Revenue level affected by the performance of the prescription-based pharmaceutical products Q1 2026 operating revenue variation: -1.5% 154.9 2.1 1.6 0.04 152.5 (6.2) €Mn Q1 2025 operating Prescription products Contrast agents & CDMO Other operating Q1 2026 operating revenue hospital products & reven
Slide 12: Gross margin uplift from R&D aid, Okedi®, lower LMWH raw material prices and the increase in CDMO activity
Gross margin uplift from R&D aid, Okedi®, lower LMWH raw material prices and the increase in CDMO activity Gross profit and Gross margin 150 +3.8 pp 100 62.3% 58.5% €Mn 40% Gross profit increased 5% to €95.0 Mn in Q1 2026. Gross margin rose by 3.8 pp to 62.3% in Q1 2026, partly driven 50 95.0 by CDT
Slide 13: SG&A with continued R&D commitment
SG&A with continued R&D commitment SG&A expenses R&D expenses +18% +79% 100 41.7% 50% 34.9% 11.2 €Mn 40% €Mn 30% 10 50 6.2 20% 54.0 63.6 10% 0 0% 0 Q1 2025 Q1 2026 Q1 2025 Q1 2026 SG&A SG&A/Operating revenue SG&A increased 18% to €63.6 Mn in Q1 2026, driven by: R&D expenses increased by 79% to €11.2
Slide 14: EBITDA, EBIT & Net Profit analysis
EBITDA, EBIT & Net Profit analysis EBITDA EBIT 32 14.9% 20% 50 19.6% 13.3% 8.0% €Mn €Mn 25 0% 16 10% 23.0 30.3 12.1 20.3 0 0 0% Q1 2025 Q1 2026 Q1 2025 Q1 2026 EBITDA EBITDA Margin EBIT EBIT Margin Net Profit 20 50 4.4 €Mn €Mn 30.3 0.1 20.3 18.1 (9.6) (4.9) 9.4 0 0 EBITDA Gross SG&A R&D Share of EBI
Slide 15: Pre-R&D analysis
Pre-R&D analysis(1) 50 -14% -20% 36.5 -22% 31.4 €Mn 29.2 23.3 23.0 18.0 0 EBITDA pre-R&D EBIT pre-R&D Net profit pre-R&D Q1 2025 Q1 2026 (1) EBITDA, EBIT and Net profit "pre-R&D" calculated excluding R&D expenses in Q1 2026 and Q1 2025. To obtain further information on the alternative performance me
Slide 16: Capital expenditure and Cash Flow
Capital expenditure and Cash Flow Main investments 26.9% 35.9% New filling lines and Q1 2026 CAPEX Evolution operations expansion €7.7 Mn 2.0% -7% vs Q1 2025 Glicopepton 35.2% ISM® Industrialisation Glicopepton New filling lines and operations expansion ISM® Industrialisation Maintenance capex 13.0
Slide 17: Debt overview
Debt overview Debt breakdown by source (%) Debt maturities 40.0 28.8 30.0 27.1 12.3% 21.2 21.1 9.1% 20.0 16.2 Total debt €Mn €114.4 Mn 10.0 78.6% 0.0 Financial liabilities for leases 2026 2027 2028 2029 2030 + Debt with public administration Bank borrowings Net debt of €14.9 Mn as of 31 March 2026 v
Slide 18: Outlook and closing remarks
Outlook and closing remarks 2026 Outlook update ROVI expects its operating revenue to increase by a low- to mid-single-digit percentage vs 2025 Strong momentum in CDMO business: consistent and focused execution Value creation from the acquisition of an injectable drug product manufacturing site in P
Slide 19: Alternative performance measures
Alternative performance measures In addition to the financial information prepared in accordance with International Financial Reporting Standards (“IFRSs”) taken from our financial statements, this document includes certain alternative performance measures (“APMs”) as defined in the ESMA (European S
Slide 20: For further information, please contact:
For further information, please contact: Juan López-Belmonte Chairman and Chief Executive Officer www.rovi.es Javier López-Belmonte Deputy Chairman and Chief Financial Officer www.rovi.es Marta Campos Head of Finance mcampos@rovi.es www.rovi.es Beatriz de Zavala Investor Relations Analyst bdezavala@
Laboratorios Farmaceuticos Rovi — Q1 2026 Earnings Presentation on 6ix